- Home
- IMNM vs EROK Comparison
IMNM vs EROK Comparison
Compare IMNM & EROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | EROK |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IMNM | EROK |
|---|---|---|
| Price | $22.12 | $20.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.80 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 224.9K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,127.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.67 | $20.06 |
| 52 Week High | $27.65 | $22.45 |
Technical Indicators
Market Signals| Indicator | IMNM | EROK |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 42.95 |
| Support Level | $19.28 | $20.11 |
| Resistance Level | $23.25 | $22.10 |
| Average True Range (ATR) | 1.36 | 1.09 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 45.98 | 10.26 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.